GALT Chief Medical Officer Khurram Jamil Buys $11K of Stock
The company's Chief Medical Officer added another block of shares to his holdings following a prior purchase earlier in the week.
Reviewed by automated data checks against the source filing. How we make and check alerts
Khurram Jamil, Chief Medical Officer at Galectin Therapeutics Inc. ($GALT), bought 4,570 shares at an average price of $2.37, worth about $10,813.99, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GALT is down 7.2% after 1 week, down 32.3% after 1 month and down 27.4% to date (from the $4.99 close on Jun 26, 2026).
GALT
Galectin Therapeutics Inc.
Key Points
- Galectin Therapeutics Inc. Chief Medical Officer Khurram Jamil bought 4,570 shares on June 26, 2026, at an average price of $2.37 per share for a total value of $10,813.99.
- The recent trade follows an earlier purchase on June 23, 2026, when Jamil acquired 7,557 shares at $1.23 apiece, alongside another insider purchase by Harold Shlevin.
- HC Wainwright & Co. maintains a buy rating on the stock with a price target of $11.00 as the clinical-stage biotech firm advances its drug candidates.
Get $GALT trade alerts by text
We text you when insiders, Congress or big funds trade $GALT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Galectin Therapeutics Inc. alert may contain errors. Disclosures
Khurram Jamil Adds More Shares of Galectin Therapeutics
Galectin Therapeutics Inc. (NasdaqCM: GALT) insider Khurram Jamil added to his position in the biotechnology firm on June 26, 2026. The company's Chief Medical Officer picked up 4,570 shares at an average price of $2.37 per share. The transaction came out to a total value of $10,813.99, according to regulatory filings with the SEC.
Following Up on Recent Insider Activity
The June 26 transaction continues a busy week of personal stock acquisitions for executive leadership at the company. Just a few days prior on June 23, 2026, Jamil bought 7,557 shares at a price of $1.23 per share, totaling $9,295.11. Another insider, Harold Shlevin, also stepped up on June 26, 2026, by purchasing 7,732 shares at $1.23 per share for a total of $9,510.36. These purchases build on a sequence of insider trades that show management putting personal capital into the clinical-stage enterprise.
Stock Price Movement and Market Levels
Shares of Galectin Therapeutics traded around $4.64 recently. The equity moves within a 52-week range defined by a low of $2.03 and a high of $7.13. Because the company focuses on early-stage drug development and does not generate traditional net income, it currently has no positive P/E ratio to display.
Analysts Set New Price Targets
Wall Street coverage of the firm remains active through individual firm updates. On June 23, 2026, HC Wainwright & Co. reiterated its buy rating on the stock alongside an $11.00 price target. The single analyst opinion currently tracking the company anchors its consensus target at that same $11.00 level.
What the Company Does
Galectin Therapeutics operates as a clinical-stage biopharmaceutical firm based in Norcross, Georgia. The organization works on creating new medical therapies targeting fibrotic diseases and cancer, with lead product candidates directed toward conditions like MASH with advanced fibrosis and cirrhosis. With a small team of employees, the business continues to advance its clinical pipeline through ongoing trials.
Looking Ahead at Corporate Milestones
Market participants will continue watching the company for clinical updates and upcoming financial disclosures. The next corporate earnings release is expected around August 11, 2025. Observers will also track future SEC reports to see how insider ownership evolves through the rest of the year.
Related Filing Alerts
Source: Khurram Jamil's Form 4 filing on $GALT (Jun 26, 2026). Find the original filing: GALT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts